Share Sanofi raised its full-year earnings outlook as Dupixent and new medicines drove growth, while stronger cash generation gives it more room to rebuild its pipeline.
$SNY INSIGHTS →

sny · signals · earnings · 3 min read · ♡ 37 · ▢ 0 · ↗ 0

Sanofi raised its full-year earnings outlook as Dupixent and new medicines drove growth, while stronger cash generation gives it more room to rebuild its pipeline.

· App research preview · Editorial standards

Read the full research in the app

A subscription is required to access the full thread.

Open in the app →
Financials
Technicals
Earnings-peers